Antibacterial and anti-inflammatory silk sutures loaded with natural active ingredients of clove and a method for their preparation
Patent Information
- Application Number
- CN202611049074.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-15
- Publication Date
- 2026-08-28
AI Technical Summary
[0003]目前主流的中药活性成分负载方式包括物理浸渍、表面喷涂、简单高分子涂层、本体共混纺丝等,但均存在固有技术缺陷,严重限制了医用应用效果
(1)本发明先通过等离子活化处理,在蚕丝缝合线基底表面构建等离子活化界面层,提升蚕丝表面活性,再利用单宁酸作为双向交联桥梁,实现没食子酸共价接枝、包埋丁香酚的微胶囊的牢固锚定,替代传统单纯物理吸附;最外层透明质酸改性壳聚糖薄膜层作为亲水防护层可有效隔绝氧气、光照与体液直接冲刷,杜绝丁香酚挥发氧化失活,解决了植物活性成分稳定性差、术中术后易脱落的技术缺陷,大幅提升产品货架期与使用稳定性;
Smart Images

Figure CN122649244A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of silk suture material technology, and in particular to an antibacterial and anti-inflammatory silk suture loaded with clove natural active ingredients and its preparation method. Background Technology
[0002] Silk sutures are widely used in surgical wound closure due to their excellent biocompatibility, biodegradability, mechanical flexibility, and tissue adhesion. To address the problems of easy bacterial colonization, significant postoperative inflammatory response, and severe scar hyperplasia associated with ordinary silk sutures, current technologies often employ methods such as loading natural plant / traditional Chinese medicine active ingredients to modify silk sutures for antibacterial and anti-inflammatory effects.
[0003] Currently, the mainstream methods for loading active ingredients of traditional Chinese medicine include physical impregnation, surface spraying, simple polymer coating, and bulk blending spinning, but all of them have inherent technical defects, which seriously limit the medical application effect. Among these methods, physical adsorption and spraying have extremely weak binding forces. Intraoperative traction and friction, as well as postoperative flushing by body fluids, can easily lead to the rapid detachment of active ingredients, resulting in low drug loading and uneven distribution. Lipid-soluble volatile oils of traditional Chinese medicine, such as eugenol and cinnamaldehyde, have poor stability, are prone to volatilization and oxidative inactivation, and conventional loading methods cannot achieve effective sealing, resulting in short product shelf life and severe loss of efficacy after sterilization. Conventional loading systems have a severe burst-release effect, with a large release of active ingredients in the early postoperative period easily irritating the wound. The efficacy decays to below the effective threshold within 3-5 days, failing to cover the high incidence of inflammation and infection during the 7-14 day postoperative period, and lacking long-term antibacterial and anti-inflammatory properties. Single active ingredients have a narrow antibacterial spectrum and a single anti-inflammatory mechanism, failing to achieve the synergistic effect of highly efficient antibacterial activity, regulation of the inflammatory microenvironment, and inhibition of scar hyperplasia. They also have weak ability to combat drug-resistant bacteria and biofilms. Chemical grafting and high-strength cross-linking modification can easily damage the structure of active ingredients in traditional Chinese medicine and impair the mechanical properties of silk. Bulk blending spinning has the problem of active ingredients being encapsulated by the protein matrix, resulting in a lack of efficacy in the early stages. In summary, existing modified silk sutures generally suffer from technical bottlenecks such as poor component stability, low bonding strength, uncontrollable release, mismatch between time and effect, and weak functional synergy, which cannot meet the multiple clinical needs for long-term anti-infection, mild anti-inflammatory, and wound healing promotion. Summary of the Invention
[0004] The purpose of this invention is to provide a method for modifying silk sutures loaded with clove's natural active ingredients to provide long-lasting antibacterial and anti-inflammatory effects. The silk sutures loaded with clove's natural active ingredients provided by this invention achieve stable encapsulation, secure loading, and time-controlled release of plant active ingredients, while also considering the mechanical properties and biocompatibility of the silk thread, thus achieving a synergistic effect of antibacterial, anti-inflammatory, and wound-healing promotion.
[0005] To achieve the above-mentioned objectives, the present invention provides the following technical solution: This invention provides an antibacterial and anti-inflammatory silk suture loaded with clove's natural active ingredients, comprising a silk suture substrate, and, from the inside out, a plasma-activated interface layer, a cross-linking anchoring layer, a clove active ingredient controlled-release layer, and a hydrophilic protective layer constructed on the surface of the silk suture substrate; the cross-linking anchoring layer is formed by cross-linking tannic acid onto the surface of the silk suture substrate; the clove active ingredient controlled-release layer is an eugenol-gallic acid composite active layer, wherein the eugenol is modified by microencapsulation, and the gallic acid is covalently grafted onto the surface of the silk fibers through cross-linking and anchoring with the cross-linking anchoring layer; the hydrophilic protective layer is a hyaluronic acid-modified chitosan film layer.
[0006] Preferably, the average thickness of the plasma-activated interface layer is 200-300 nm, and the average thickness of the cross-linked anchoring layer is 150-200 nm.
[0007] Preferably, the average thickness of the controlled-release layer of clove active ingredients is 400-600 nm, and the average thickness of the hydrophilic protective layer is 300-400 nm.
[0008] Preferably, the microcapsules encapsulating eugenol have a particle size of 2-5 μm, the microcapsules use gelatin and gum arabic as wall materials, and the encapsulation efficiency of the microcapsules is ≥85%.
[0009] Preferably, the mass ratio of hyaluronic acid to modified chitosan in the hyaluronic acid-modified chitosan film layer is 1:(25~50).
[0010] This invention provides a method for preparing antibacterial and anti-inflammatory silk sutures loaded with clove natural active ingredients as described in any of the above technical solutions, comprising the following steps: S1. After the medical silk suture is subjected to high-temperature degumming, cleaning and drying in sequence, a silk suture base is obtained; The silk suture substrate is subjected to plasma activation treatment to form a plasma activation interface layer on the surface of the silk suture substrate, thereby obtaining activated silk suture. S2. Mix gelatin, gum arabic, and deionized water to obtain a wall material solution; After mixing the wall material solution and eugenol, the mixture was subjected to emulsification and homogenization, pH adjustment, low-temperature curing, cross-linking and shaping, static precipitation and post-treatment in sequence to obtain microcapsules encapsulated with eugenol. The microcapsules containing eugenol were dispersed in deionized water to obtain an aqueous dispersion of eugenol microcapsules. S3. The activated silk suture obtained in step S1 is immersed in a tannic acid buffer solution for cross-linking to form a cross-linked anchoring layer on the surface of the activated silk suture. After removal, it is immersed in a gallic acid solution for covalent grafting. After removal, it is immersed in the eugenol microcapsule dispersion obtained in step S2 for ultrasonication to form a controlled-release layer of eugenol active ingredients on the surface of the cross-linked anchoring layer, thus obtaining a loaded silk suture. S4. Mix hyaluronic acid, chitosan and glacial acetic acid solution, stir and let stand to remove bubbles in sequence to obtain coating solution; Using the coating liquid, the loaded silk suture obtained in step S3 is coated with a uniform lifting and coating process to form a hydrophilic protective layer on the surface of the loaded silk suture. Then, it is subjected to low-temperature vacuum drying and sterilization in sequence to obtain antibacterial and anti-inflammatory silk suture loaded with clove natural active ingredients.
[0011] Preferably, the parameters for the plasma activation treatment in step S1 are: carried out in an air atmosphere, with a power of 80~120W, a vacuum degree of 60~100Pa, and a treatment time of 4~7min.
[0012] Preferably, the rotation speed of the emulsification homogenization in step S2 is 7000~9000 r / min, and the emulsification homogenization time is 8~14 min.
[0013] Preferably, in step S3, the concentration of tannic acid in the tannic acid buffer solution is 0.8~1.2wt%, the pH of the tannic acid buffer solution is 6.8, the crosslinking temperature is room temperature, and the crosslinking time is 25~40min.
[0014] Preferably, the parameters for wrapping in step S4 are: lifting speed of 2~4cm / s, drying time of a single wrapping of 13~20min, and repeated wrapping of 2~3 times.
[0015] Compared with the prior art, the present invention has the following advantages: (1) In this invention, a plasma-activated interface layer is first constructed on the surface of the silk suture base through plasma activation treatment to enhance the surface activity of the silk. Then, tannic acid is used as a two-way cross-linking bridge to achieve the firm anchoring of gallic acid covalent grafted and eugenol-encapsulated microcapsules, replacing the traditional simple physical adsorption. The outermost hyaluronic acid modified chitosan film layer serves as a hydrophilic protective layer that can effectively isolate oxygen, light and direct flushing of body fluids, prevent eugenol from volatilization and inactivation, solve the technical defects of poor stability of plant active ingredients and easy shedding during and after surgery, and greatly improve the product shelf life and use stability. (2) This invention can effectively inhibit the initial drug release by setting an outer hydrophilic protective layer to avoid wound irritation; in the early postoperative period, the hydrophilic protective layer slowly degrades and releases a small amount of clove active ingredients to achieve immediate antibacterial and anti-inflammatory effects; during the high-incidence period of inflammation from 7 to 14 days after surgery, the internally anchored microcapsules gradually rupture and the covalently grafted components slowly dissociate, continuously releasing an effective dose of active substances, perfectly covering the wound infection and high-incidence period of inflammation, achieving controllable drug release in sequence, matching the full cycle of wound healing, and solving the problems of short drug efficacy and mismatch in sequence of traditional modified silk threads; (3) Eugenol used in this invention has broad-spectrum antibacterial and analgesic effects, and can effectively inhibit Staphylococcus aureus, drug-resistant bacteria and biofilm formation. Gallic acid has excellent anti-inflammatory, antioxidant and collagen repair-promoting effects, and can regulate macrophage polarization and reduce scar hyperplasia. The combination of the two has a synergistic effect, taking into account the triple effects of antibacterial, anti-inflammatory and repair-promoting. The combination system achieves functional synergy, which solves the defects of narrow antibacterial spectrum and single anti-inflammatory mechanism of single Chinese medicine components. (4) The present invention uses natural and mild raw materials to construct a modified system on the surface of the silk suture base. There are no toxic chemical crosslinking agents or inorganic heavy metal particles left, and the biosafety is high. The mild crosslinking modification can strengthen the structure of silk fibers, make up for the mechanical damage problem of traditional modified silk threads, and have stable dry and wet strength and firm knots. It takes into account both mechanical properties and biocompatibility, and adapts to clinical needs to meet the surgical suturing needs of different parts. (5) The present invention adopts low temperature modification and low temperature sterilization process, which can retain the activity of plant active ingredients to the greatest extent, solves the industry problem of significant reduction in efficacy after sterilization of traditional Chinese medicine modified silk thread, has good batch stability, is compatible with medical sterilization process, has strong industrialization feasibility, and is suitable for large-scale production. Attached Figure Description
[0016] Figure 1 The bar chart shows the drug retention rates at 7 days and 14 days for the antibacterial and anti-inflammatory silk sutures prepared in Examples 1-3 and the modified silk thread samples prepared in Comparative Examples 1-3 of this invention. Figure 2 This is a bar graph showing the 14-day wound healing rate of the antibacterial and anti-inflammatory silk sutures prepared in Examples 1-3 and the modified silk thread samples prepared in Comparative Examples 1-3. Detailed Implementation
[0017] This invention provides an antibacterial and anti-inflammatory silk suture loaded with clove's natural active ingredients, comprising a silk suture substrate, and, from the inside out, a plasma-activated interface layer, a cross-linking anchoring layer, a clove active ingredient controlled-release layer, and a hydrophilic protective layer constructed on the surface of the silk suture substrate; the cross-linking anchoring layer is formed by cross-linking tannic acid onto the surface of the silk suture substrate; the clove active ingredient controlled-release layer is an eugenol-gallic acid composite active layer, wherein the eugenol is modified by microencapsulation, and the gallic acid is covalently grafted onto the surface of the silk fibers through cross-linking and anchoring with the cross-linking anchoring layer; the hydrophilic protective layer is a hyaluronic acid-modified chitosan film layer.
[0018] In this invention, the thickness of the plasma-activated interface layer is preferably 200-300 nm, the thickness of the cross-linking anchoring layer is preferably 150-200 nm, the thickness of the controlled-release layer of eugenol active ingredients is preferably 400-600 nm, and the thickness of the hydrophilic protective layer is preferably 300-400 nm. This invention controls the thickness of each layer to improve the antibacterial and anti-inflammatory effects of the prepared silk suture while achieving stable encapsulation, firm loading, and time-controlled release of plant active ingredients, taking into account the mechanical properties and biocompatibility of the suture, thus achieving a triple synergistic effect of antibacterial, anti-inflammatory, and wound-healing promotion. In this invention, the particle size of the microcapsules encapsulating eugenol is preferably 2-5 μm, the microcapsules preferably use gelatin and gum arabic as wall materials, and the encapsulation rate of the microcapsules is preferably ≥85%. This invention, by controlling the particle size, wall material type, and encapsulation rate of microcapsules, is beneficial during the high-incidence period of inflammation (7-14 days post-surgery). The internally anchored microcapsules gradually rupture, and the covalently grafted components slowly dissociate, continuously releasing an effective dose of active substances. This perfectly covers the wound infection and inflammation peak period, achieving controllable drug release in sequence, matching the entire wound healing cycle, and solving the problems of short-term efficacy and mismatched timing of traditional modified sutures. In this invention, the mass ratio of hyaluronic acid to modified chitosan in the hyaluronic acid-modified chitosan film layer is 1:(25-50). By controlling this mass ratio, this invention effectively isolates the product from oxygen, light, and direct flushing by body fluids, preventing the volatilization and oxidation of eugenol. This overcomes the technical defects of poor stability and easy detachment of plant active ingredients during and after surgery, significantly improving product shelf life and usage stability.
[0019] This invention provides a method for preparing the antibacterial and anti-inflammatory silk suture loaded with clove natural active ingredients as described in the above-mentioned technical solution, comprising the following steps: S1. After the medical silk suture is subjected to high-temperature degumming, cleaning and drying in sequence, a silk suture base is obtained; The silk suture substrate is subjected to plasma activation treatment to form a plasma activation interface layer on the surface of the silk suture substrate, thereby obtaining activated silk suture. S2. Mix gelatin, gum arabic, and deionized water to obtain a wall material solution; After mixing the wall material solution and eugenol, the mixture was subjected to emulsification and homogenization, pH adjustment, low-temperature curing, cross-linking and shaping, static precipitation and post-treatment in sequence to obtain microcapsules encapsulated with eugenol. The microcapsules containing eugenol were dispersed in deionized water to obtain an aqueous dispersion of eugenol microcapsules. S3. The activated silk suture obtained in step S1 is immersed in a tannic acid buffer solution for cross-linking to form a cross-linked anchoring layer on the surface of the activated silk suture. After removal, it is immersed in a gallic acid solution for covalent grafting. After removal, it is immersed in the eugenol microcapsule dispersion obtained in step S2 for ultrasonication to form a controlled-release layer of eugenol active ingredients on the surface of the cross-linked anchoring layer, thus obtaining a loaded silk suture. S4. Mix hyaluronic acid, chitosan and glacial acetic acid solution, stir and let stand to remove bubbles in sequence to obtain coating solution; Using the coating liquid, the loaded silk suture obtained in step S3 is coated with a uniform lifting and coating process to form a hydrophilic protective layer on the surface of the loaded silk suture. Then, it is subjected to low-temperature vacuum drying and sterilization in sequence to obtain antibacterial and anti-inflammatory silk suture loaded with clove natural active ingredients.
[0020] This invention involves sequentially subjecting medical silk sutures to high-temperature degumming, cleaning, and drying to obtain a silk suture substrate; then subjecting the silk suture substrate to plasma activation treatment to form a plasma activation interface layer on the surface of the silk suture substrate, thereby obtaining an activated silk suture.
[0021] In this invention, the high-temperature degumming preferably includes: mixing medical silk sutures and a 0.5wt% sodium carbonate aqueous solution at a solid-liquid ratio of 1:50 g / mL, and then boiling at 95-99°C for 25-35 minutes to degumme. This invention does not impose any special restrictions on the cleaning method, as long as it removes residual sodium carbonate and sericin impurities. In this invention, the drying is preferably performed under vacuum at 55-60°C for 3-5 hours. In this invention, the plasma activation treatment parameters are preferably: performed in an air atmosphere, with a power of 80-120 W, a vacuum degree of 60-100 Pa, and a treatment time of 4-7 minutes. By controlling the parameters of the plasma activation treatment, this invention achieves the construction of a high-roughness, high-activity plasma-activated interface layer of a certain thickness on the surface of the silk suture substrate, enhancing the surface activity of the silk and facilitating the subsequent formation of a cross-linking anchoring layer.
[0022] This invention involves mixing gelatin, gum arabic, and deionized water to obtain a wall material solution; mixing the wall material solution with eugenol, and then sequentially performing emulsification homogenization, pH adjustment, low-temperature curing, cross-linking and shaping, static precipitation, and post-treatment to obtain microcapsules encapsulated with eugenol; and dispersing the microcapsules encapsulated with eugenol in deionized water to obtain an aqueous dispersion of eugenol microcapsules.
[0023] In this invention, the mass ratio of gelatin to gum arabic is preferably 1:1; the total concentration of gelatin and gum arabic in the wall material solution is 3wt%~5wt%. In this invention, the rotation speed of the emulsification homogenization is preferably 7000~9000 r / min, and the emulsification homogenization time is preferably 8~14 min. This invention, by controlling the rotation speed and time of the emulsification homogenization, facilitates the subsequent preparation of microcapsules with uniform particle size. In this invention, the pH adjustment is preferably done using a 10% glacial acetic acid solution to adjust the pH of the emulsified homogenized product to 4.5. In this invention, the low-temperature curing temperature is preferably 8~12℃, the low-temperature curing rotation speed is preferably 200~300 r / min, and the low-temperature curing time is preferably 50~60 min. In this invention, the reagent used for crosslinking and setting is preferably a 2.5wt% glutaraldehyde solution; the crosslinking and setting time is preferably 25~35 min. This invention, by controlling the reagents and time for cross-linking and shaping, facilitates the acquisition of microcapsules with distinct and uniform particle size and an encapsulation efficiency ≥85%. This invention does not impose any particular restrictions on the method of static precipitation, as long as complete precipitation is achieved. In this invention, the post-processing preferably includes sequentially filtering and freeze-drying the product after static precipitation. This invention does not impose any particular restrictions on the filtration method, as long as solid-liquid separation is achieved without damaging the integrity of the microcapsules. In this invention, the freeze-drying time is preferably 22~26 hours. In this invention, the concentration of microcapsules in the eugenol microcapsule aqueous dispersion is preferably 0.6wt%~1.2wt%.
[0024] After obtaining the activated silk suture and the eugenol microcapsule dispersion, the present invention immerses the activated silk suture in a tannic acid buffer solution for cross-linking, thereby forming a cross-linked anchoring layer on the surface of the activated silk suture. After removal, it is immersed in a gallic acid solution for covalent grafting, and then immersed in the eugenol microcapsule dispersion for ultrasonication, thereby forming a controlled-release layer of eugenol active ingredients on the surface of the cross-linked anchoring layer, thus obtaining the loaded silk suture.
[0025] In this invention, the concentration of tannic acid in the tannic acid buffer solution is preferably 0.8~1.2wt%, the pH of the tannic acid buffer solution is preferably 6.8, the crosslinking temperature is preferably room temperature, and the crosslinking time is preferably 25~40 min. In this invention, the crosslinking is preferably carried out under low-speed oscillation. This invention promotes the anchoring and crosslinking of tannic acid on the surface of activated silk sutures by controlling the concentration and pH of the tannic acid buffer solution, as well as the temperature, time, and conditions of the crosslinking, forming a crosslinking anchoring layer of a certain thickness, which is beneficial for subsequent grafting of gallic acid and loading of microcapsules, increasing their loading capacity. In this invention, the gallic acid solution is preferably an aqueous solution of gallic acid and ethanol with a gallic acid concentration of 1.5wt%~2.5wt%; the volume ratio of ethanol to deionized water in the gallic acid solution is preferably 3:7; the covalent grafting temperature is preferably 35~40℃, and the covalent grafting time is preferably 1.5~3 h. This invention promotes stable grafting by controlling the time and temperature of covalent grafting, thereby facilitating covalent bonding between the phenolic hydroxyl groups of gallic acid and the amino and tannic acid active groups of silk fibroin. In this invention, the preferred ultrasonic temperature is 32-36°C, the preferred ultrasonic power is 150W, and the preferred ultrasonic time is 20-30 minutes. This invention controls the temperature, power, and time of ultrasonication to prevent microcapsule sedimentation and increase the microcapsule loading capacity. Preferably, after ultrasonication, the invention further includes allowing the ultrasonic product to stand and solidify for 15-25 minutes.
[0026] After obtaining the loaded silk suture, the present invention mixes hyaluronic acid, modified chitosan and glacial acetic acid solution, and stirs and allows them to stand for degassing in sequence to obtain a coating liquid; using the coating liquid, the loaded silk suture is coated with a uniform speed lifting coating process to form a hydrophilic protective layer on the surface of the loaded silk suture, and then subjected to low temperature vacuum drying and sterilization in sequence to obtain antibacterial and anti-inflammatory silk suture loaded with clove natural active ingredients.
[0027] In this invention, the preferred method for preparing the modified chitosan includes the following steps: Medical-grade chitosan with a degree of deacetylation ≥92% and a molecular weight of 60-90 kDa is dissolved in a 1 wt% glacial acetic acid aqueous solution and stirred at a constant temperature of 45-50°C for 3 hours to obtain a 4 wt% chitosan solution; hyaluronic acid powder with a molecular weight of 2000 Da is added to the chitosan solution at a mass ratio of chitosan to hyaluronic acid of 37.5:1, and the mixture is stirred at a low speed of 300 r / min; 0.25 wt% citric acid is added as a natural grafting crosslinking agent, and the grafting reaction is carried out at a constant temperature of 45-55°C in a water bath for 2-4 hours; after the reaction, the mixture is purified by dialysis using a dialysis bag for 22-26 hours, and then freeze-dried to obtain the modified chitosan. In this invention, the concentration of the glacial acetic acid solution is preferably 1 wt%; the mass ratio of the modified chitosan to the volume of the glacial acetic acid solution is (5-10) g: 100 mL. In this invention, the preferred coating parameters are: a lifting speed of 2-4 cm / s, a single coating drying time of 13-20 min, and 2-3 repeated coating cycles. This invention controls the coating parameters to form a dense hydrophilic protective layer of a certain thickness. In this invention, after coating, it is preferable to further include air-drying the coated product at 25°C for 3 hours. In this invention, the low-temperature vacuum drying is preferably performed at 35-42°C for 1.5-3 hours. In this invention, the sterilization is preferably performed using ethylene oxide at 35°C for 10-14 hours. This invention, through low-temperature vacuum drying and low-temperature sterilization, preserves the activity of eugenol in the microcapsules, solving the industry problem of significant efficacy reduction after sterilization of traditional Chinese medicine modified silk threads, and exhibiting good batch stability.
[0028] The technical solutions of this invention will be clearly and completely described below with reference to the embodiments thereof. Obviously, the described embodiments are only a part of the embodiments of this invention, and not all of them. All other embodiments obtained by those skilled in the art based on the embodiments of this invention without creative effort are within the scope of protection of this invention.
[0029] Unless otherwise specified, all experiments were repeated three times, and the results are expressed as averages.
[0030] Example 1 An antibacterial and anti-inflammatory silk suture loaded with clove's natural active ingredients comprises a silk suture base and, from the inside out, a plasma-activated interface layer, a cross-linking anchoring layer, a clove active ingredient controlled-release layer, and a hydrophilic protective layer constructed on the surface of the silk suture base. The cross-linking anchoring layer is formed by cross-linking tannic acid onto the surface of the silk suture base. The clove active ingredient controlled-release layer is a eugenol-gallic acid composite active layer, wherein the eugenol is modified by microencapsulation, and the gallic acid is covalently grafted onto the surface of the silk fibers through cross-linking and anchoring with the cross-linking anchoring layer. The hydrophilic protective layer is a hyaluronic acid-modified chitosan film layer. The average thickness of the plasma-activated interface layer is 250 nm, the average thickness of the cross-linked anchoring layer is 180 nm, the average thickness of the clove active ingredient controlled-release layer is 500 nm, and the average thickness of the hydrophilic protective layer is 350 nm.
[0031] The preparation method of the antibacterial and anti-inflammatory silk suture loaded with clove natural active ingredients includes the following steps: S1. Select 4-0 medical natural silk sutures and immerse them in a 0.5wt% sodium carbonate aqueous solution at a solid-liquid ratio of 1:50 (g / mL). Boil at 98℃ for 30 minutes to degumme the sutures. Rinse them three times with deionized water at room temperature and vacuum dry them at 60℃ for 4 hours to obtain a completely degummed and purified silk suture substrate. Place the silk suture substrate in a low-temperature air plasma treatment instrument with a power of 100W, a vacuum degree of 80Pa, an air atmosphere, and a treatment time of 5 minutes to form a plasma-activated interface layer with an average thickness of 250nm on the surface. Remove and seal the substrate for later use. S2. Weigh 2.0g of gelatin and 2.0g of gum arabic, dissolve them separately in 100mL of room temperature deionized water, and mix them after complete dissolution to obtain a wall material solution; add 3.0g of eugenol to the wall material solution, emulsify and homogenize at 8000r / min for 10min to form a uniform emulsion; adjust the pH to 4.5 with 10% glacial acetic acid, cool to 10℃, and stir at 300r / min for low-temperature curing for 60min; then add 0.5g of glutaraldehyde in a 2.5wt% glutaraldehyde solution for cross-linking and shaping for 30min, allow to stand for precipitation, filter, and freeze-dry for 24h to obtain microcapsules encapsulated with eugenol with an average particle size of 3μm and an encapsulation rate of 90%; disperse the microcapsules encapsulated with eugenol in deionized water to obtain an aqueous dispersion of eugenol microcapsules with a concentration of 0.8wt%; S3. Prepare a 1.0wt% tannic acid phosphate buffer solution (pH=6.8). Immerse the activated silk suture in the tannic acid buffer solution at a solid-liquid ratio of 1:40 (g / mL) and crosslink at room temperature (25℃) for 30 minutes to form a crosslinked anchoring layer on the surface of the activated silk suture. After removal, gently rinse to remove free tannic acid. Immerse in a 2.0wt% gallic acid ethanol aqueous solution (ethanol to water volume ratio of 3:7) and perform covalent grafting at 40℃ for 2 hours. After removal, immerse in the eugenol microcapsule dispersion for ultrasonication. Set the ultrasonic temperature to 35℃, ultrasonic power to 150W, and ultrasonic time to 30 minutes, with low-speed stirring throughout to prevent sedimentation. After ultrasonication, allow to stand at room temperature for 20 minutes to solidify, forming a controlled-release layer of eugenol active ingredients on the surface of the crosslinked anchoring layer, thus obtaining the loaded silk suture. S4. The preparation steps of modified chitosan are as follows: Take medical-grade chitosan with a deacetylation degree ≥92% and a molecular weight of 80kDa, dissolve it in a 1wt% aqueous solution of glacial acetic acid, and stir at 45℃ for 3h to obtain a chitosan solution with a concentration of 4wt%; according to the mass ratio of chitosan to hyaluronic acid of 37.5:1, add hyaluronic acid powder with a molecular weight of 2000Da to the chitosan solution, stir and mix at a low speed of 300r / min, add 0.25wt% citric acid as a natural grafting crosslinking agent, and perform grafting reaction at 45℃ for 3h. After the reaction, dialyze and purify the chitosan using a dialysis bag for 24h, and freeze-dry to obtain modified chitosan. Weigh 5.0g of modified chitosan and 0.2g of hyaluronic acid, dissolve them in 100mL of 1% glacial acetic acid aqueous solution, stir at room temperature for 4h, and let stand for 2h to remove bubbles to obtain a coating solution. Using the coating solution, a uniform speed lifting and coating process is used, with a uniform speed of 3cm / s for lifting and coating. Each coating is air-dried for 15min, and the coating is repeated twice to coat the loaded silk suture. Then, it is slowly air-dried and cured at 25℃ for 3h to form a hydrophilic protective layer on the surface of the loaded silk suture. Then, it is vacuum dried at 40℃ for 2h, sterilized at 35℃ with ethylene oxide for 12h, and then vacuum aseptically packaged to obtain antibacterial and anti-inflammatory silk suture loaded with clove natural active ingredients.
[0032] Example 2 Antibacterial and anti-inflammatory silk suture loaded with clove natural active ingredients was prepared according to the method of Example 1. The difference from Example 1 is that the amount of eugenol was adjusted to 5.0g, the amount of modified chitosan was adjusted to 7.5g, and the amount of hyaluronic acid was kept at 0.2g.
[0033] Example 3 Antibacterial and anti-inflammatory silk suture loaded with clove natural active ingredients was prepared according to the method of Example 1. The difference from Example 1 is that the amount of eugenol was adjusted to 8.0g and the amount of modified chitosan was adjusted to 10g.
[0034] Comparative Example 1 A method for preparing a single modified silk thread, comprising the following steps: Activated silk sutures were prepared according to the method in Example 1; The activated silk suture was immersed in an equal volume of unembedded pure eugenol ethanol solution (5g eugenol, 100mL anhydrous ethanol) at a solid-liquid ratio of 1:40 (g / mL) and statically soaked at room temperature (25℃) for 2 hours. After soaking, it was removed and air-dried naturally, then vacuum-dried at 40℃ for 2 hours. It was then treated with the same low-temperature ethylene oxide sterilization process as in Example 1 to obtain a single modified silk suture.
[0035] Comparative Example 2 Gallic acid-grafted modified silk thread was prepared according to the method of Example 1. The difference from Example 1 is that the microcapsules containing eugenol were omitted. The covalently grafted silk was directly cured at room temperature and then a hydrophilic protective layer was formed according to the same operation and parameters.
[0036] Comparative Example 3 A modified silk thread, prepared according to the method of Example 1, differs from Example 1 in that it has no hydrophilic protective layer, and the loaded silk suture is directly subjected to low-temperature vacuum drying, low-temperature sterilization and vacuum aseptic packaging in sequence.
[0037] Performance test experiments and results The antibacterial and anti-inflammatory silk sutures prepared in Examples 1-3 and the modified silk threads prepared in Comparative Examples 1-3 were subjected to uniform performance testing. The test indicators included: drug retention rate (7 days, 14 days), antibacterial rate (Staphylococcus aureus, MRSA-resistant bacteria), inflammatory factor inhibition rate, suture mechanical retention rate, and wound healing rate. The test results are shown in Table 1 and below. Figure 1 , 2 As shown.
[0038] The performance testing methods are as follows: Retention rate of active drug: High performance liquid chromatography (HPLC); Antibacterial rate of bacteria: Thin film covering method (GB / T 31402-2015 Standard for Testing the Antibacterial Properties of Plastics); Inhibition rate of inflammatory factor IL-6: Detection method using enzyme-linked immunosorbent assay (ELISA); Retention rate of dry and wet mechanical strength of sutures: Tensile test method using a universal testing machine (YY 0167-2020 National Standard for Absorbable Surgical Sutures); Animal wound healing rate: Image area analysis method using a full-thickness skin defect wound model in SD rats.
[0039] Table 1. Statistical analysis of performance test results of the antibacterial and anti-inflammatory silk sutures prepared in the examples and the modified silk thread prepared in the comparative examples.
[0040] In summary, compared with Comparative Example 1, which uses traditional physical impregnation, Examples 1-3 of the present invention, through the composite structure of microcapsule encapsulation, cross-linking anchoring, and protective layer locking, have increased the drug retention rate by more than 7 times after 14 days, completely solving the problem of rapid loss and inactivation of active ingredients in traditional Chinese medicine, and significantly improving long-term stability. Compared to Comparative Example 2, which is modified with gallic acid alone, the compound system in Examples 1-3 of this invention has a broader antibacterial spectrum, with an antibacterial rate of nearly 50% higher against drug-resistant MRSA strains. At the same time, its anti-inflammatory and repair-promoting properties are significantly optimized, demonstrating the synergistic effect of the compound active system. Compared to Comparative Example 3 without a protective layer, the hydrophilic protective layer in Examples 1-3 of this invention can effectively delay drug release and isolate external interference, greatly improving the retention rate and duration of action of active ingredients, solving the core pain points of drug burst release and rapid inactivation. The dry and wet strength retention rates of each example of this invention are all higher than 88%, proving that the method of this invention does not damage the mechanical properties of the silk substrate, taking into account both functional modification and clinical performance.
[0041] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. An antibacterial and anti-inflammatory silk suture loaded with clove natural active ingredients, characterized in that, The product includes a silk suture substrate, and on the surface of the silk suture substrate, a plasma-activated interface layer, a cross-linking anchoring layer, a eugenol active ingredient controlled-release layer, and a hydrophilic protective layer are constructed sequentially from the inside out. The cross-linking anchoring layer is formed by cross-linking tannic acid onto the surface of the silk suture substrate. The eugenol active ingredient controlled-release layer is a eugenol-gallic acid composite active layer, wherein the eugenol is modified by microencapsulation, and the gallic acid is covalently grafted onto the surface of the silk fiber through cross-linking and anchoring with the cross-linking anchoring layer. The hydrophilic protective layer is a hyaluronic acid-modified chitosan film layer.
2. The antibacterial and anti-inflammatory silk suture according to claim 1, characterized in that, The average thickness of the plasma-activated interface layer is 200-300 nm, and the average thickness of the cross-linked anchoring layer is 150-200 nm.
3. The antibacterial and anti-inflammatory silk suture according to claim 1, characterized in that, The average thickness of the controlled-release layer of clove active ingredients is 400~600nm, and the average thickness of the hydrophilic protective layer is 300~400nm.
4. The antibacterial and anti-inflammatory silk suture according to claim 1, characterized in that, The microcapsules encapsulating eugenol have a particle size of 2-5 μm, and the microcapsules use gelatin and gum arabic as wall materials, with an encapsulation efficiency of ≥85%.
5. The antibacterial and anti-inflammatory silk suture according to claim 1, characterized in that, The mass ratio of hyaluronic acid to modified chitosan in the hyaluronic acid-modified chitosan film layer is 1:(25~50).
6. A method for preparing an antibacterial and anti-inflammatory silk suture loaded with clove natural active ingredients as described in any one of claims 1 to 5, characterized in that, Includes the following steps: S1. After the medical silk suture is subjected to high-temperature degumming, cleaning and drying in sequence, a silk suture base is obtained; The silk suture substrate is subjected to plasma activation treatment to form a plasma activation interface layer on the surface of the silk suture substrate, thereby obtaining activated silk suture. S2. Mix gelatin, gum arabic, and deionized water to obtain a wall material solution; After mixing the wall material solution and eugenol, the mixture was subjected to emulsification and homogenization, pH adjustment, low-temperature curing, cross-linking and shaping, static precipitation and post-treatment in sequence to obtain microcapsules encapsulated with eugenol. The microcapsules containing eugenol were dispersed in deionized water to obtain an aqueous dispersion of eugenol microcapsules. S3. The activated silk suture obtained in step S1 is immersed in a tannic acid buffer solution for cross-linking to form a cross-linked anchoring layer on the surface of the activated silk suture. After removal, it is immersed in a gallic acid solution for covalent grafting. After removal, it is immersed in the eugenol microcapsule dispersion obtained in step S2 for ultrasonication to form a controlled-release layer of eugenol active ingredients on the surface of the cross-linked anchoring layer, thus obtaining a loaded silk suture. S4. Mix hyaluronic acid, chitosan and glacial acetic acid solution, stir and let stand to remove bubbles in sequence to obtain coating solution; Using the coating liquid, the loaded silk suture obtained in step S3 is coated with a uniform lifting and coating process to form a hydrophilic protective layer on the surface of the loaded silk suture. Then, it is subjected to low-temperature vacuum drying and sterilization in sequence to obtain antibacterial and anti-inflammatory silk suture loaded with clove natural active ingredients.
7. The preparation method according to claim 6, characterized in that, The parameters for the plasma activation treatment in step S1 are as follows: the treatment is carried out in an air atmosphere, with a power of 80~120W, a vacuum degree of 60~100Pa, and a treatment time of 4~7min.
8. The preparation method according to claim 6, characterized in that, In step S2, the rotation speed of the emulsification homogenization is 7000~9000 r / min, and the emulsification homogenization time is 8~14 min.
9. The preparation method according to claim 6, characterized in that, In step S3, the concentration of tannic acid in the tannic acid buffer solution is 0.8~1.2wt%, the pH of the tannic acid buffer solution is 6.8, the crosslinking temperature is room temperature, and the crosslinking time is 25~40min.
10. The preparation method according to claim 6, characterized in that, The parameters for the wrapping in step S4 are: lifting speed of 2-4 cm / s, drying time of a single wrapping of 13-20 min, and repeated wrapping of 2-3 times.
